Abstract
Alzheimer's disease (AD) is a progressive neurodegenerative disorder of the brain associated with memory impairment, progressive cognitive decline and changes in personality and behavior, with rising incidence among elderly people. Reflecting the world population ageing, the scenario is expected to worsen in the next decades if novel drugs or mechanisms that help to counteract neurodegeneration will not be identified. The complex neuropathology of AD is characterized by cholinergic loss, extracellular deposition of amyloid-β plaques, formation of intracellular neurofibrillary tangles, chronic brain inflammation and oxidative damage. To date, there are no effective treatments that can slow or halt the disease, and currently approved drugs only seem to act as palliative by temporary ameliorating cognitive impairment. On the other hand, the role played by other biological systems in the pathogenetic process is now clearly growing and, as knowledge on how AD develops and triggers brain damage proceeds, drug discovery attempts to identify new potential therapeutic targets. This review will focus on these emerging strategies, some of which could open new therapeutic perspectives in Alzheimer’s disease, adding new elements for the medicinal chemist to handle and combine for the design of novel multi-target-directed ligands able to simultaneously modulate ‘old classic’ and newly identified targets.
Keywords: Alzheimer’s disease, amyloid beta peptide, endocannabinoid system, epigenetic modulation, HAT, HDAC, PDE, PPARγ.
Current Topics in Medicinal Chemistry
Title:Emerging Targets in Neurodegeneration: New Opportunities for Alzheimer's Disease Treatment?
Volume: 13 Issue: 15
Author(s): Angela Rampa, Silvia Gobbi, Federica Belluti and Alessandra Bisi
Affiliation:
Keywords: Alzheimer’s disease, amyloid beta peptide, endocannabinoid system, epigenetic modulation, HAT, HDAC, PDE, PPARγ.
Abstract: Alzheimer's disease (AD) is a progressive neurodegenerative disorder of the brain associated with memory impairment, progressive cognitive decline and changes in personality and behavior, with rising incidence among elderly people. Reflecting the world population ageing, the scenario is expected to worsen in the next decades if novel drugs or mechanisms that help to counteract neurodegeneration will not be identified. The complex neuropathology of AD is characterized by cholinergic loss, extracellular deposition of amyloid-β plaques, formation of intracellular neurofibrillary tangles, chronic brain inflammation and oxidative damage. To date, there are no effective treatments that can slow or halt the disease, and currently approved drugs only seem to act as palliative by temporary ameliorating cognitive impairment. On the other hand, the role played by other biological systems in the pathogenetic process is now clearly growing and, as knowledge on how AD develops and triggers brain damage proceeds, drug discovery attempts to identify new potential therapeutic targets. This review will focus on these emerging strategies, some of which could open new therapeutic perspectives in Alzheimer’s disease, adding new elements for the medicinal chemist to handle and combine for the design of novel multi-target-directed ligands able to simultaneously modulate ‘old classic’ and newly identified targets.
Export Options
About this article
Cite this article as:
Rampa Angela, Gobbi Silvia, Belluti Federica and Bisi Alessandra, Emerging Targets in Neurodegeneration: New Opportunities for Alzheimer's Disease Treatment?, Current Topics in Medicinal Chemistry 2013; 13 (15) . https://dx.doi.org/10.2174/15680266113139990143
DOI https://dx.doi.org/10.2174/15680266113139990143 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Preface
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Rheumatoid Arthritis: An Autoimmune Disease with Female Preponderance and Cardiovascular Risk Equivalent to Diabetes Mellitus: Role of Cardiovascular Magnetic Resonance
Inflammation & Allergy - Drug Targets (Discontinued) An Update on the Roles of the Complement System in Autoimmune Diseases and the Therapeutic Possibilities of Anti-Complement Agents
Current Drug Therapy ACE and ACE2 in Inflammation: A Tale of Two Enzymes
Inflammation & Allergy - Drug Targets (Discontinued) Reactive Oxygen Species in Pathogenesis of Atherosclerosis
Current Pharmaceutical Design Cannabinoids and Myocardial Ischemia: Novel insights, Updated Mechanisms, and Implications for Myocardial Infarction
Current Medicinal Chemistry Emerging Treatment Strategies and Potential Therapeutic Targets in Primary Sjogrens Syndrome
Inflammation & Allergy - Drug Targets (Discontinued) Anti-CD20 Antibody in Primary Sjogren's Syndrome Managemen
Current Pharmaceutical Biotechnology A PHACES Syndrome Unmasked by Propranolol Interruption in a Tetralogy of Fallot Patient: Case Report and Extensive Review on New Indications of Beta Blockers
Current Medicinal Chemistry Immunomodulation in Inflammatory Neuropathies: Rationale and Safety
Current Drug Safety Anterior Uveitis with Negative Work-up: Giant Cell Arteritis Remains the Pet Peeve
Current Rheumatology Reviews Novel Systemic Drugs for Cutaneous T-Cell Lymphoma
Recent Patents on Anti-Cancer Drug Discovery Resveratrol: A Therapeutic Promise for Cardiovascular Diseases
Recent Patents on Cardiovascular Drug Discovery Exosomes: A Novel Therapeutic Paradigm for the Treatment of Depression
Current Drug Targets The Antioxidant Effects of Radix Astragali (Astragalus membranaceus and Related Species) in Protecting Tissues from Injury and Disease
Current Drug Targets Involvement of the Toxic AGEs (TAGE)-RAGE System in the Pathogenesis of Diabetic Vascular Complications: A Novel Therapeutic Strategy
Current Drug Targets Mapping Myeloperoxidase to Identify its Promiscuity Properties Using Docking and Molecular Dynamics Simulations
Current Pharmaceutical Design Practical Approach to Children Presenting with Eosinophila and Hypereosinophilia
Current Pediatric Reviews Free Radicals Generated by Post-Prandial Oxidative Burst in the Early Alterations of Vascular Contractility
Clinical Immunology, Endocrine & Metabolic Drugs (Discontinued) Serum Procalcitonin Levels in Febrile Patients with Systemic Autoimmune Diseases
Current Rheumatology Reviews